PT - JOURNAL ARTICLE AU - S Edsbäcker AU - P Andersson AU - C Lindberg AU - J Paulson AU - A Ryrfeldt AU - A Thalén TI - Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. DP - 1987 May 01 TA - Drug Metabolism and Disposition PG - 403--411 VI - 15 IP - 3 4099 - http://dmd.aspetjournals.org/content/15/3/403.short 4100 - http://dmd.aspetjournals.org/content/15/3/403.full SO - Drug Metab Dispos1987 May 01; 15 AB - The metabolism of budesonide, (22RS)-16 alpha, 17 alpha-butylidenedioxy-11 beta,21-dihydroxypregna-1,4-diene- 3,20-dione, was studied in the 9000g supernatant fraction of livers from rat, mouse, and man. The two budesonide C-22 epimers produced different metabolites. This was explained by substrate-selective oxidation of the nonsymmetric 16 alpha, 17 alpha-acetal substituent. Epimer 22R gave 16 alpha-hydroxyprednisolone, while epimer 22S produced a metabolite tentatively identified as 23-hydroxybudesonide. Otherwise, budesonide followed the general metabolic pathways reported for synthetic glucocorticoids. Thus, oxidative metabolism predominated, 6 beta-hydroxybudesonide and delta 6-budesonide being identified in all investigated species. Reductive metabolism, giving 4,5 beta-dihydrobudesonide and 3,4,5 beta-tetrahydrobudesonide, was most pronounced in the rat. Rates and routes of budesonide metabolism were most similar in mouse and human livers. This implies that the mouse is a more relevant species than the rat in studies of the pharmacology and toxicology of budesonide.